Natalizumab for GVHD: too little or too late?
Kevin Quann1, Faruk Sacirbegovic2,3, Warren D Shlomchik1,3,4
1Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Blood Advances
|September 12, 2023
Abstract
No abstract available in PubMed .


